JAMA Oncology Author Interviews
JAMA Network
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Episodes
Mentioned books
Jun 6, 2016 • 6min
Outcomes for Biomarker-Based Treatment Strategies in Refractory Malignant Neoplasms
Interview with Razelle Kurzrock, MD, author of Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis
Jun 2, 2016 • 5min
Physiologic Frailty in Hematopoietic Cell Transplantation Patients
Interview with Smita Bhatia, MD, MPH, author of Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study
May 19, 2016 • 7min
Lifestyle Associations With US Cancer Incidence and Mortality
Interview with Mingyang Song, MD, ScD, author of Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among Whites in the United States
Apr 14, 2016 • 18min
Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases
Mar 24, 2016 • 10min
Prostate-Specific Antigen Screening and Selective Treatment
Interview with Ruth Etzioni, PhD, author of Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies, and Andrew J. Vickers, PhD, author of Does Prostate-Specific Antigen Screening Do More Good Than Harm? Depends on How You Do It
Mar 3, 2016 • 4min
Effect of Long-term Use of Aspirin on the Risk for Cancer
Interview with Andrew T. Chan, MD, MPH, author of Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer
Feb 11, 2016 • 6min
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
Interview with Ann H. Partridge, MD, MPH, author of BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
Jan 28, 2016 • 12min
Molecular Profiling in Pediatric Tumors
Interview with Katherine A. Janeway, MD, MSc, author of Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study, and D. Williams Parsons, MD, PhD, author of Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors
Dec 10, 2015 • 9min
Delayed Initiation of Chemotherapy and Breast Cancer
Interview with Mariana Chavez-MacGregor, MD, MSc, author of Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer, and Richard J. Bleicher, MD, author of Time to Surgery and Breast Cancer Survival in the United States
Nov 5, 2015 • 12min
Erlotinib and the Risk of Oral Cancer
Interview with William N. William Jr, MD, and Scott M. Lippman, MD, author of Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial
